HCM
VRTX icon

Harvey Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Harvey Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,000
Closed -$725K – 80
2021
Q3 		$725K Buy
+4,000
New +$781K 0.25% 54
2013
Q4 		– Sell
-8,600
Closed -$652K – 81
2013
Q3 		$652K Hold
8,600
– – 0.33% 43
2013
Q2 		$688K Buy
+8,600
New +$633K 0.43% 43

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Harvey Capital Management's VRTX Position: Q4 2021 in Review

Harvey Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2021, closing a stake of 4,000 shares — an estimated $725K sold.

Harvey Capital Management first reported a position in VRTX in Q2 2013 and held it in 3 quarters. The position peaked at $725K in Q3 2021. 1,033 funds tracked by Wall St. Rank hold VRTX as of Q4 2021.

  • Harvey Capital Management reported no remaining Vertex Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Harvey Capital Management sold 4,000 Vertex Pharmaceuticals shares in Q4 2021, an estimated $725K.
  • Harvey Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Harvey Capital Management's Vertex Pharmaceuticals position peaked at $725K in Q3 2021.
  • 1,033 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2021.

Based on Harvey Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.